

CLINICAL RESEARCH NEWSLETTER

March 2026
 Volume III



Symptom Science High Priority Study

URCC-24060

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

Cancer-related cognitive impairment (CRCI) is common and distressing among cancer survivors. Cancer survivors experience trouble with thinking and memory. Individuals with chronic leukemias are vulnerable to CRCI.

Eligibility:

- Cancer survivor with chronic myelogenous leukemia (CML) or chronic lymphocytic leukemia (CLL) about to begin TKI therapy.
- 18 years +
- No history of metastatic cancer, primary brain tumor, or brain radiation
- No history of TKI therapy
- No history of Cytotoxic Chemotherapy, immune checkpoint inhibitor therapy, hormonal therapy, biologic therapy, radiotherapy within the past 5 years.

Colorectal Cancer Awareness Month

In recognition of Colorectal Cancer awareness month, we highlight the importance of both awareness and research in improving patient outcomes. Campaigns like “Weird Looking Stools” Campaign encourage individuals to pay attention to changes in stool appearance and seek screening when appropriate. Through the GA NCORP and partners such as Georgia CORE, patients across community sites have access to innovative clinical trials aimed at advancing prevention, detection, and treatment of colorectal cancer.



Table of Contents

TOPIC	PAGE
Study Spotlight/Colorectal Awareness/Contact info	1
Research Based Meetings	2
Trials Pending Activation	3
Recently Activated/Recommended Trials	4
All Open and Enrolling CCDR Trials	5
Test Your Knowledge Quiz/Site Recognition	6

Contact Info
Alaina Newsome;
underberga@sjchs.org
GA NCORP CCDR
Program Coordinator

CLINICAL RESEARCH NEWSLETTER

March 2026
 Volume 3



Upcoming Research Base Meetings*

Research Base	Date	Location
NRG	July 16-18, 2026	Denver, CO
SWOG	April 30-May 2, 2026	San Francisco, CA
	October 8-10, 2026	Chicago, IL
ECOG	May 5-7, 2026	Baltimore, MD
	October 20 - 22, 2026	Philadelphia, PA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
UPCOMING ROUTINE AUDITS ¹		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit preparation.

ECOG-ACRIN Spring Meeting

The ECOG-ACRIN Clinical Research Associates (CRA) Core Committee has limited funds available to provide travel assistance to the upcoming meeting in Baltimore, MD, Tuesday, May 5–Thursday, May 7, 2026. Four candidates will be selected to receive a travel expense reimbursement award of up to \$1000. These funds are intended to facilitate attendance to the ECOG-ACRIN meetings for CRAs with no other form of travel support. Data managers, clinical research associates or clinical research coordinators/nurses (who do their own data) are eligible to apply. Only one candidate per institution will be supported.

CLINICAL RESEARCH NEWSLETTER

March 2026
 Volume 3



TRIALS PENDING ACTIVATION

Research Base	Title
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors
	EAQ181: Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings
	EAQ161CD: Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting
Alliance	A222302: Family Communications After Genetic Testing
SWOG	S2424CD: Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams

It often develops slowly. Colorectal cancer can take 10–15 years to develop from a small polyp into cancer.

Colorectal cancer is one of the most preventable cancers. Because doctors can remove precancerous polyps during screening, it is one of the few cancers that can be stopped before it develops.

Interesting Fact About Colorectal Cancer

Your gut bacteria may play a role. Researchers are studying how the gut microbiome may influence colorectal cancer risk and response to treatment.

Cases are rising in younger adults. Doctors are seeing increasing rates of colorectal cancer in people under age 50, which led to updated screening recommendations.

CLINICAL RESEARCH NEWSLETTER

March 2026
 Volume 3



Recently Activated and Recommended Trials¹

Research Base	Title	CTSU Activation Date
SWOG	LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	10/22/2025
	S2433: Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma	12/26/2025
ECOG	EA1241: Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol	12/4/2025
	EA6232: Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma	2/20/2026
NRG	NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	1/12/2026
	NRG-HN015: A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)	1/12/2026
Alliance	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
	A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL)	12/23/2025
	A212101: Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer	3/5/2026
Wake Forest	WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	12/02/2025
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025



CLINICAL RESEARCH NEWSLETTER

March 2026
 Volume 3



ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS¹

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) Deemed high priority by the Executive Committee.	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) Sites must receive approval prior to initiating any study start-up activities.	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/23/2024
	WF-2402CD: Collaborative Oncology between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets (CORRECT)	2/20/2026
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025



CLINICAL RESEARCH NEWSLETTER

March 2026
Volume 3

TEST OF YOUR KNOWLEDGE QUIZ!

The first person to answer correctly will receive **Georgia NCORP swag** and a shout-out in the next issue! Send your responses to kdixon@georgiacore.org.

1. What is the primary difference between a solid tumor and a hematologic malignancy?

- A. Solid tumors arise from bone marrow cells
- B. Solid tumors form masses in organs or tissues, whereas hematologic cancers affect blood and lymph systems
- C. Solid tumors only occur in the lungs
- D. Hematologic malignancies form localized tumors

2. What does metastasis refer to in solid tumor cancers?

- A. Tumor shrinking after treatment
- B. Spread of cancer cells from the primary site to distant organs
- C. Cancer limited to one organ
- D. A benign tumor

3. Which of the following is considered a targeted therapy used in solid tumor treatment?

- A. Cisplatin
- B. Trastuzumab
- C. Cyclophosphamide
- D. Doxorubicin

Investigator & Site Recognition

Congratulations to all of the Investigators and the Northside Hospital and St. Joseph Candler Teams for their enrollment efforts in the WF2304-A172401 (COSMIC) study. Their proactive patient screening processes and strong multidisciplinary collaboration have set a model for network excellence.

We also recognize our research nurses and data managers, whose dedication ensures protocol compliance and data integrity across all sites.

Feburary Winners

Huge shoutout to our 2 winners from last months Test Your Knowlegde...

Judi Wilder (Pearlman)

and

Kasia LechJohnson (NSH)

Way to go !

Who will be our winner this month?